What is it about?
Lung cancer is a critical health threat and the leading cause of cancer-related deaths globally. Adoptive cell therapy (ACT), which utilizes genetically engineered T cells, including tumor-infiltrating lymphocytes (TIL therapy) and chimeric antigen receptor-modified T (CAR-T) cells, represents a groundbreaking immunotherapy technique. This approach offers the most promising advancements in cancer treatment, achieving unparalleled success in hematological malignancies.
Featured Image
Photo by Robina Weermeijer on Unsplash
Why is it important?
Recent developments in adoptive T-cell therapy (T-CT) research have significantly advanced our understanding of the molecular basis for effective lung cancer management. These innovations include the use of tumor-infiltrating lymphocytes (TIL) and chimeric antigen receptor-modified T (CAR-T) cells, which have shown great promise. Despite these advancements, several challenges remain that must be addressed to optimize the clinical use of TIL and CAR-T cell therapy against lung cancer. Looking ahead, future research directions focus on overcoming these obstacles, enhancing the efficacy of T-CT, and ensuring its successful integration into clinical practice.
Perspectives
My personal journey in writing about "Adoptive T-Cell Therapy for the Treatment of Lung Cancer" stems from a profound commitment to advancing cancer therapeutics and improving patient outcomes. In recent years, I have closely followed the developments in adoptive T-cell therapy (T-CT) research, particularly the use of tumor-infiltrating lymphocytes (TIL) and chimeric antigen receptor-modified T (CAR-T) cells. These groundbreaking techniques have not only revolutionized the field of immunotherapy but have also offered new hope for patients battling hematological malignancies. Inspired by these unparalleled results, I embarked on this writing project to explore the potential of T-CT in treating lung cancer.
Dr. Priyal Soni
Amity University
Read the Original
This page is a summary of: Adoptive T-Cell Therapy for the Treatment of Lung Cancer, January 2024, Springer Science + Business Media,
DOI: 10.1007/978-981-99-7141-1_7.
You can read the full text:
Contributors
The following have contributed to this page
